Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Intratumor heterogeneity: seeing the wood for the trees.

Intratumor heterogeneity: seeing the wood for the trees. Most advanced solid tumors remain incurable, with resistance to chemotherapeutics and targeted therapies a common cause of poor clinical outcome. Intratumor heterogeneity may contribute to this failure by initiating phenotypic diversity enabling drug resistance to emerge and by introducing tumor sampling bias. Envisaging tumor growth as a Darwinian tree with the trunk representing ubiquitous mutations and the branches representing heterogeneous mutations may help in drug discovery and the development of predictive biomarkers of drug response. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Science translational medicine Pubmed

Intratumor heterogeneity: seeing the wood for the trees.

Science translational medicine , Volume 4 (127): 11441701 – Sep 28, 2012

Intratumor heterogeneity: seeing the wood for the trees.


Abstract

Most advanced solid tumors remain incurable, with resistance to chemotherapeutics and targeted therapies a common cause of poor clinical outcome. Intratumor heterogeneity may contribute to this failure by initiating phenotypic diversity enabling drug resistance to emerge and by introducing tumor sampling bias. Envisaging tumor growth as a Darwinian tree with the trunk representing ubiquitous mutations and the branches representing heterogeneous mutations may help in drug discovery and the development of predictive biomarkers of drug response.

Loading next page...
 
/lp/pubmed/intratumor-heterogeneity-seeing-the-wood-for-the-trees-3eWuC35Vj7

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1946-6234
eISSN
1946-6242
DOI
10.1126/scitranslmed.3003854
pmid
22461637

Abstract

Most advanced solid tumors remain incurable, with resistance to chemotherapeutics and targeted therapies a common cause of poor clinical outcome. Intratumor heterogeneity may contribute to this failure by initiating phenotypic diversity enabling drug resistance to emerge and by introducing tumor sampling bias. Envisaging tumor growth as a Darwinian tree with the trunk representing ubiquitous mutations and the branches representing heterogeneous mutations may help in drug discovery and the development of predictive biomarkers of drug response.

Journal

Science translational medicinePubmed

Published: Sep 28, 2012

There are no references for this article.